Novo Nordisk’s Semaglutide Hits Phase III Marks In NASH

 
• By Joseph Haas
  
Novo Nordisk's semaglutide hits both primary endpoints in a Phase III NASH study (Shutterstock)

More from Clinical Trials

More from Therapy Areas